Brand News
MLB approves CBD sponsorships in landmark change for sports leagues
MLB and its teams are now free to sell CBD sponsorships, a development likely to echo across the industry and open a new sponsorship category in pro sports. League officials told team marketers that CBDs are henceforth an “approved category” as long as they are certified by testing organization NSF to not have psychoactive levels of THC.
MLB is looking to grab a piece of the growing CBD market in the U.S. It’s unknown at this time what MLB teams or the league could get for a CBD deal. One optimistic estimate has the entire CBD market at $4.9B worldwide this year, exploding to $47B in ’28.
Kemin Industries Introduces Luxiva™ Hemp CBD Distillates
Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, announced the launch of Luxiva™ hemp cannabidiol (CBD) distillates. The line includes two hemp CBD distillates that are farmed and produced in America’s heartland and are United States Department of Agriculture (USDA)-certified organic.
Kemin Luxiva™ Full Spectrum CBD Distillates are organic, hemp-based ingredient solutions that have been developed for the U.S. and global health and wellness markets.
In An Effort To Democratize Plant-Based Wellness, Equilibria Lowers Prices And Offers Free One-on-One Consults For All
Equilibria, a leading functional wellness company specializing in personalized support for all members, believes that wellness should be a priority, not a luxury, announced a permanent price reduction on many products including all bundles and subscriptions, now available for up to 45% off MSRP.
“During this stressful time of escalating costs in most aspects of our consumer life, it’s more important than ever that access to high-quality wellness products are within reach. We’ve worked incredibly hard with our premium supply chain to make Equilibria more affordable because when taken daily, our personalized wellness routines are transforming women’s lives,” said Coco Meers, CEO and co-founder of Equilibria.
Trend Pieces & Editorial
The Quest by Circadian Medicine to Make the Most of Our Body Clocks
- Circadian rhythms, in other words, are relevant to more than sleep. But few realized how relevant until 2014, when a professor of pharmacology at the University of Pennsylvania named John Hogenesch published a paper with his colleagues showing that almost half of the genes in mice produce proteins on a 24-hour schedule.
- This means that as the clock genes cycle through their functions, their work is activating or deactivating thousands of other, non clock genes in consistent daily patterns. The finding astonished circadian experts.
- After giving a talk about the paper at a conference, Hogenesch went to the bathroom and encountered at the urinal Horacio de la Iglesia, a prominent biologist at the University of Washington with decades of circadian research to his name. De la Iglesia was incredulous about what he had just heard. Until then, it was thought that at most 30 percent of our genome was under circadian regulation. The mouse study implied that the number was far greater. “This was a mind-blowing idea,” de la Iglesia says.
“New generation” of consumers driving demand for ingestible skincare, research shows
- Demand for ingestible products is growing as consumers adopt more holistic attitudes to skincare, research by Lycored has found.
- The research suggests that growing demand for beauty-from-within is rooted in increasingly holistic, health-focused attitudes to skincare. Seven in ten (70%) of the survey respondents said they used skincare products to keep their skin healthy and 69% said it was “to feel good about myself.” This “feelgood factor” was particularly evident among consumers in the 18-24 age bracket, 82% of whom said they used products to feel good about themselves, and women (78% compared to 59% of men).
- Caroline Schroeder, Marketing Communications Manager at Lycored, said: “The new generation of skincare consumers is much more interested in holistic skin health than traditional cosmetic signs of beauty. This focus on ‘from within’ factors has increased in recent years, especially during the pandemic, during which many consumers have valued overall health and self-care more than outward appearance. It’s a major reason for the boom in demand for ingestible skincare.”
Updates About Industry
Regulation
Johnson & Johnson asks FDA to ‘chip away’ at cannabinoid regulations
Drugmaker Johnson & Johnson has joined the chorus of businesses asking U.S. health regulators to develop basic safety rules for cannabinoids in foods and dietary supplements.
Speaking Tuesday to an advisory panel of the U.S. Food and Drug Administration, an executive at the company’s pharmaceutical arm suggested the FDA could “start to chip away” at the unanswered questions about cannabinoids such as CBD.
Minnesota House Leader Says New Law Allowing THC Edibles Was ‘Intentional’ Step Toward Marijuana Legalization
The Democratic leader of the Minnesota House of Representatives said that passing the state’s newly enacted law allowing low-THC edibles for adults was an “intentional” legislative step meant to open the door to broader marijuana legalization that is opposed by many Republican colleagues who ultimately voted for the incremental reform.
At a press briefing, House Majority Leader Ryan Winkler (DFL), who has consistently championed legalization in the legislature, emphasized that the new legislation was debated and passed in a public forum, so GOP members who have since expressed reservations about the edibles provisions after voting in favor of the bill don’t exactly have an excuse.
The Latest
Category & Research Trends
CBN And CBG Sales See Rapid Growth As CBD Sales Slow In Cannabis Markets
- BDSA Consumer data show that cannabis consumers have become more knowledgeable about minor cannabinoids in cannabis products and their potential benefits – in the Fall of 2019 only 11% were familiar with CBN and only 8% were familiar with CBG, however by Fall 2021 familiarity of CBN increased to 14% and familiarity of CBG increased to 13%.
- In Q1 2022 there were ~70% more products containing CBN than there were in Q1 2021 across CA, CO, IL, MA, MI, NV, and OR, and in Q1 2022 there were more than twice as many products containing CBG than there were in Q1 2021 in those markets.
Largest Cannabinoid Trial On Pain Finds Significant Improvement
The OBX Pain Study on CBD and Rare Cannabinoids is the largest ever randomized, controlled clinical trial of cannabinoids for pain, involving more than 1600 participants from across the U.S. and the first of its kind to examine the synergistic impact of rare cannabinoids like Cannabichromene (CBC) and Cannabigerol (CBG) on pain.
The trial included 6 product arms, which all contained CBD at 40 mg per serving. Most arms also contained varying levels of rare cannabinoids, including CBG and CBC.
InMed says peer-reviewed study highlights potential role of rare cannabinoids THCV, CBC on skin conditions
- The researchers used a widely recognized in vitro model of human keratinocytes, and studied how these cannabinoids interacted with several receptors including cannabinoid receptors and other endocannabinoid system components.
- Each cannabinoid had distinct biological activity via the endocannabinoid system, the researchers said.
- THCV was shown to perform as a cannabinoid receptor 1 antagonist and have a high affinity for the human transient receptor potential vanilloid .
CBDistillery Announces Groundbreaking Research Finding CBG + CBD Can Significantly Reduce Temporary Anxiety
Balanced Health Botanicals™, parent-company of top-selling cannabinoid brand CBDistillery™, and a wholly owned subsidiary of Village Farms International today announced the results from a Pathfinder Mission that analyzed the impact of CBDistillery’s Daytime Synergy 500mg CBG + 500mg CBD tincture on mild or temporary anxiety. This Pathfinder Mission was conducted in collaboration with MoreBetter (dba Releaf App™) and comes at a time when consumers suffering with anxiety is at an all-time high, impacting nearly 40 million adults in the U.S.
Study Finds All Water-Soluble CBD Formulations Are Not Created Equal For Pharmacokinetic Absorption
Caliper Foods, the pioneer of fast-acting, scientifically backed, water soluble cannabinoids, recently completed a clinical research study in partnership with Colorado State University in which findings showed that formulation design makes a significant difference in pharmacokinetics—the rate and amount of CBD absorbed into the body. The study also found that consumption of food significantly increased pharmacokinetic absorption of Caliper Foods’ proprietary formulation of water-soluble cannabidiol (CBD).
Receptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder
Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD).
Open Book Extracts & Biopharmaceutical Research Company Establish Research & Development Collaboration
Under the terms of the collaboration, OBX will leverage BRC’s research platforms, in order to develop research-backed formulations and products including Delta-9 THC.
From preclinical and first-in-human (FIH) dosage forms to optimization of formulations for late-stage development and market following clinical evaluation, OBX will work closely with BRC to develop the most appropriate formulation based on the physicochemical and biopharmaceutics properties of the cannabinoids of interest, the intended route of administration and the phase of development.
Scheduled
Events
August
8 – 11
CG 42nd Annual Growth Conference
Boston, MA
August
23 – 25
Cannabis Conference
Las Vegas, NV
September
6 – 8
ICDP – International Cannabinoid-Derived Pharmaceuticals Summit
Boston, MA
September
13 – 14
Benziga Cannabis Capital Conference
Chicago, IL
